杰龙制药
GERN
1.17
-0.06
-4.88%
杰龙制药
US · GERN
#3440 按市值排名
1.17
-0.06
-4.88%
实时 - 追踪5344个代码 - 心跳于529秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 74.84% +0.01pp
- 机构数量
- 291
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund35.68%
Hedge Fund22.30%
VC/PE Fund9.19%
Public Company6.12%
Private Company0.91%
Insurance Company0.30%
Government Pension Fund0.27%
Other25.08%
主要股东 截至 2026-06-30
BlackRock
7.64% · 49.12M 股
RA Capital Management, L.P.
6.66% · 42.81M 股
Soleus Capital Management, L.P.
6.66% · 42.81M 股
State Street Global Advisors
5.58% · 35.86M 股
Vanguard Capital Management, LLC
4.86% · 31.21M 股
Citadel Advisors LLC
4.52% · 29.04M 股
ClearBridge Investments, LLC
3.06% · 19.65M 股
Eversept Partners, L.P.
2.91% · 18.72M 股
The Goldman Sachs Group, Inc.
2.48% · 15.94M 股
Geode Capital Management, LLC
2.27% · 14.56M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 46次买入 · 3次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Robert Jay Spiegel | Independent Director | 0.03% |
| Susan Molineaux | Independent Director | 0.02% |
| James Ziegler | Executive Vice President | 0.02% |
| Elizabeth O'Farrell | Lead Independent Director | 0.01% |
| Scott Samuels | Executive Vice President | 0.00% |
| Michelle Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | 0.00% |
| V. Lawlis | Independent Director | 0.00% |
| Ahmed ElNawawi | Executive Vice President | 0.00% |
| Gaurav Aggarwal | Director | -- |
| Joseph Eiden | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Robert Jay Spiegel | Independent Director | Other Acquisition | +6,351 | $1.23 |
| 2026-06-29 | Robert Jay Spiegel | Independent Director | Other Acquisition | +6,103 | $1.28 |
| 2026-05-19 | Elizabeth O'Farrell | Lead Independent Director | Other Derivative Acquisition | +220,000 | $1.26 |
| 2026-05-19 | Robert Jay Spiegel | Independent Director | Other Derivative Acquisition | +220,000 | $1.26 |
| 2026-05-19 | Susan Molineaux | Independent Director | Other Derivative Acquisition | +220,000 | $1.26 |
| 2026-05-19 | John McDonald | Independent Director | Other Derivative Acquisition | +220,000 | $1.26 |
| 2026-05-19 | Dawn Bir | Independent Director | Other Derivative Acquisition | +220,000 | $1.26 |
| 2026-04-12 | Timothy Williams | Executive Vice President | Other Derivative Acquisition | +2,500,000 | $1.73 |
| 2026-03-30 | Robert Jay Spiegel | Independent Director | Other Acquisition | +5,243 | $1.49 |
| 2026-03-24 | Patricia Susan Andrews | Director | Other Derivative Acquisition | +270,000 | $1.57 |
| 2026-03-24 | Constantine Chinoporos | Director | Other Derivative Acquisition | +270,000 | $1.57 |
| 2026-02-17 | Michelle Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | Derivative Exercise and Sale | -9,855 | $1.94 |
| 2026-02-17 | Michelle Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | Derivative Exercise and Retained | +17,645 | -- |
| 2026-02-16 | Joseph Eiden | -- | Other Derivative Acquisition | +2,220,000 | $1.80 |
| 2026-02-16 | Michelle Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | Other Derivative Acquisition | +1,660,000 | $1.80 |
| 2025-12-30 | Robert Jay Spiegel | Independent Director | Other Acquisition | +5,918 | $1.32 |
| 2025-12-14 | James Ziegler | Executive Vice President | Intent to Sell (Form 144) | -20,000 | $1.37 |
| 2025-10-19 | Ahmed ElNawawi | Executive Vice President | Other Derivative Acquisition | +3,000,000 | $1.27 |
| 2025-10-19 | Ahmed ElNawawi | Executive Vice President | Initial Statement of Beneficial | 0 | -- |
| 2025-09-29 | Robert Jay Spiegel | Independent Director | Other Acquisition | +5,702 | $1.37 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
杰龙制药 讨论区 0 条评论